Wuxi AppTec CoFRA:WX8 -0.06%96 EBITDA Margin % is 45.34% as of Mar. 2026, which is 41% above its 10-year median of 32.07. GuruFocus rates FRA:WX8 with a GF Score™ of 96/100 and a GF Value™ of ¥11.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 98.52% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Wuxi AppTec Co's EBITDA for the
three
months ended in Mar. 2026 was ¥5,638 Mil. Wuxi AppTec Co's Revenue for the
three
months ended in Mar. 2026 was ¥12,436 Mil. Therefore, Wuxi AppTec Co's EBITDA margin for the quarter that ended in Mar. 2026 was 45.34%.
Wuxi AppTec Co (FRA:WX8) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wuxi AppTec Co EBITDA Margin % Related Terms
Wuxi AppTec Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:WX8 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (FRA:WX8) has a EBITDA Margin % of 45.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuxi AppTec Co and its competitors. This is 41% above median its historical median of 32.07. Over the past decade, Wuxi AppTec Co's EBITDA Margin % has ranged from 25.68 to 60.91. According to the industry distribution chart, Wuxi AppTec Co ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 1.5%.
Is Wuxi AppTec Co's EBITDA Margin % too high?
Wuxi AppTec Co's current EBITDA Margin % of 45.34% is 41% above median its 10-year median of 32.07. Over the past 10 years, this metric has ranged from a low of 25.68 to a high of 60.91. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Wuxi AppTec Co's value of 45.34% is 806.8% above this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 96/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #3 out of 203 companies for EBITDA Margin %. This places Wuxi AppTec Co in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Wuxi AppTec Co's value of 45.34% is 806.8% above this benchmark. Historically, Wuxi AppTec Co's own EBITDA Margin % has ranged from 25.68 to 60.91 over the past decade. While the company's 10-year median is 32.07 vs. the industry median of 5.00, Wuxi AppTec Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current EBITDA Margin % of 45.34% is 806.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current EBITDA Margin % is 45.34%, which is 41% above median its own 10-year median of 32.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (FRA:WX8) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥11.53, compared to a current price of ¥16.01 — trading 38.8% above its estimated fair value. The current EBITDA Margin % is 45.34%, which is 41% above median its 10-year median of 32.07 and 806.8% above the Medical Diagnostics & Research industry median of 5.00. Wuxi AppTec Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wuxi AppTec Co (FRA:WX8), the current EBITDA Margin % is 45.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (FRA:WX8) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of ¥16.01 is trading 38.8% above its estimated GF Value™ of ¥11.53.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for FRA:WX8:
EBITDA Margin %: 45.34% (41% above median its 10-year median of 32.07)
GF Value™: ¥11.53 vs. price of ¥16.01 (38.8% above fair value)
Industry Position: 806.8% above the Medical Diagnostics & Research median (#3 of 203)
No single metric tells the full story. See the FRA:WX8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
96GF Score
Get the complete analysis for FRA:WX8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WX8 has been successfully added to your 
